董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Seymour Liebman | 男 | Director | 74 | 4.92万美元 | 未持股 | 2023-07-21 |
| Thierry Bernard | 男 | Director | 58 | 5.92万美元 | 未持股 | 2023-07-21 |
| John Sperzel | 男 | Chairman of the Board,Chief Executive Officer,President and Director | 59 | 198.53万美元 | 未持股 | 2023-07-21 |
| Ninfa Saunders | 女 | Director | 71 | 5.92万美元 | 未持股 | 2023-07-21 |
| Robin Toft | 女 | Director | 62 | 6.92万美元 | 未持股 | 2023-07-21 |
| Laura Adams | 女 | Director | 67 | 4.92万美元 | 未持股 | 2023-07-21 |
| Jack Cumming | 男 | Director | 78 | 10.64万美元 | 未持股 | 2023-07-21 |
| David B. Elsbree | 男 | Director | 76 | 6.92万美元 | 未持股 | 2023-07-21 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Michael Gibbs | 男 | Senior Vice President and General Counsel | 52 | 76.73万美元 | 未持股 | 2023-07-21 |
| John Sprague | 男 | Chief Financial Officer | 64 | 76.23万美元 | 未持股 | 2023-07-21 |
| John Sperzel | 男 | Chairman of the Board,Chief Executive Officer,President and Director | 59 | 198.53万美元 | 未持股 | 2023-07-21 |
| Roger Smith | 男 | Senior Vice President of Science Research and Development | 58 | 未披露 | 未持股 | 2023-07-21 |
| Brett Giffin | 男 | Chief Commercial Officer | 65 | 未披露 | 未持股 | 2023-07-21 |
董事简历
中英对照 | 中文 | 英文- Seymour Liebman
-
Seymour Liebman，担任Canon U.S.A., Inc.的执行副总裁。
Seymour Liebman,has served as a member of T2 Biosystems, Inc. Board of Directors since September 2016. Mr. Liebman has been employed by Canon USA, Inc., a leading provider of consumer, business-to-business, and industrial imaging solutions to the United States and to the Latin American and the Caribbean markets, since 1974 and currently serves as the Executive Vice President, Chief Administrative Officer and General Counsel and Senior Managing Executive Officer of Canon Inc., Japan. Mr. Liebman received his J.D. from Touro Law School, his M.S. in mathematics from Rutgers University, his M.S. in accounting from Long Island University and his B.A. in mathematics from Hofstra University. - Seymour Liebman，担任Canon U.S.A., Inc.的执行副总裁。
- Seymour Liebman,has served as a member of T2 Biosystems, Inc. Board of Directors since September 2016. Mr. Liebman has been employed by Canon USA, Inc., a leading provider of consumer, business-to-business, and industrial imaging solutions to the United States and to the Latin American and the Caribbean markets, since 1974 and currently serves as the Executive Vice President, Chief Administrative Officer and General Counsel and Senior Managing Executive Officer of Canon Inc., Japan. Mr. Liebman received his J.D. from Touro Law School, his M.S. in mathematics from Rutgers University, his M.S. in accounting from Long Island University and his B.A. in mathematics from Hofstra University.
- Thierry Bernard
-
Thierry Bernard自2020年6月以来一直担任我们的董事会成员。Bernard先生自2015年2月起受聘于QIAGEN NV（分子诊断，应用测试以及学术和制药研究的样品和分析技术提供商），并于2020年3月被任命为首席执行官。从2014年8月到2015年2月，他曾任职Daktari Diagnostics公司（护理诊断点公司），在那里他曾担任首席执行官。从1998年4月到2014年8月，Bernard先生受聘于BIOM&233；Rieux，一家体外诊断公司，在那里他担任越来越重要的职务，最近担任企业Vice President，全球商业运营，投资者关系和大中华地区。他曾获得巴黎政治经济学院（Sciences PO Paris）的国际经济与金融学学士学位，欧洲学院（College of Europe）的管理与经济学硕士学位，伦敦经济学院（London School of Economics）的国际经济学硕士学位，来自巴塞罗那大学的Dess Comercio External和哈佛商学院高级管理课程AMP177学位。
Thierry Bernard,has served as a member of T2 Biosystems, Inc. Board of Directors since June 2020. Mr. Bernard has been employed by Qiagen NV, a provider of sample and assay technologies for molecular diagnostics, applied testing, and academic and pharmaceutical research since February 2015 and was named Chief Executive Officer in March 2020. From August 2014 to February 2015, Mr. Bernard was employed by Daktari Diagnostics, a point of care diagnostics company, where he served as Chief Executive Officer. From April 1998 to August 2014, Mr. Bernard was employed by bioMérieux, an in vitro diagnostics company, where he served in roles of increasing responsibility, most recently as Corporate Vice President, Global Commercial Operations, Investor Relations and the Greater China Region. He has earned a BS International Economics & Finance from Sciences Po Paris, an MSc Administration & Economics from the College of Europe, an MSc International Economics from the London School of Economics, a DESS Comercio Exterior from Universidad de Barcelona and a degree from the Advanced Management Program (AMP) 177 at Harvard Business School. - Thierry Bernard自2020年6月以来一直担任我们的董事会成员。Bernard先生自2015年2月起受聘于QIAGEN NV（分子诊断，应用测试以及学术和制药研究的样品和分析技术提供商），并于2020年3月被任命为首席执行官。从2014年8月到2015年2月，他曾任职Daktari Diagnostics公司（护理诊断点公司），在那里他曾担任首席执行官。从1998年4月到2014年8月，Bernard先生受聘于BIOM&233；Rieux，一家体外诊断公司，在那里他担任越来越重要的职务，最近担任企业Vice President，全球商业运营，投资者关系和大中华地区。他曾获得巴黎政治经济学院（Sciences PO Paris）的国际经济与金融学学士学位，欧洲学院（College of Europe）的管理与经济学硕士学位，伦敦经济学院（London School of Economics）的国际经济学硕士学位，来自巴塞罗那大学的Dess Comercio External和哈佛商学院高级管理课程AMP177学位。
- Thierry Bernard,has served as a member of T2 Biosystems, Inc. Board of Directors since June 2020. Mr. Bernard has been employed by Qiagen NV, a provider of sample and assay technologies for molecular diagnostics, applied testing, and academic and pharmaceutical research since February 2015 and was named Chief Executive Officer in March 2020. From August 2014 to February 2015, Mr. Bernard was employed by Daktari Diagnostics, a point of care diagnostics company, where he served as Chief Executive Officer. From April 1998 to August 2014, Mr. Bernard was employed by bioMérieux, an in vitro diagnostics company, where he served in roles of increasing responsibility, most recently as Corporate Vice President, Global Commercial Operations, Investor Relations and the Greater China Region. He has earned a BS International Economics & Finance from Sciences Po Paris, an MSc Administration & Economics from the College of Europe, an MSc International Economics from the London School of Economics, a DESS Comercio Exterior from Universidad de Barcelona and a degree from the Advanced Management Program (AMP) 177 at Harvard Business School.
- John Sperzel
-
John Sperzel自2020年1月起担任我们的总裁兼首席执行官兼董事会成员。2014年3月至2020年1月，Sperzel先生担任ChembioDiagnostics，Inc.的首席执行官、总裁兼董事会成员，该公司是一家专注于传染病的定点诊断公司。从2011年9月到2013年12月，Sperzel先生担任International Technidyne Corporation的首席执行官兼总裁，这是一家护理点心血管诊断测试解决方案的开发商。Sperzel先生在普利茅斯州立学院（Plymouth State College）获得工商管理/管理理学学士学位。
John Sperzel,has served as T2 Biosystems, Inc. President and Chief Executive Officer and a member of T2 Biosystems, Inc. Board of Directors since January 2020 and has served as Chairman of T2 Biosystems, Inc. Board of Directors since July 2021. From March 2014 to January 2020, Mr. Sperzel was the Chief Executive Officer, President and a member of the Board of Directors of Chembio Diagnostics, Inc., a point-of-care diagnostics company focused on infectious diseases. From September 2011 to December 2013, Mr. Sperzel was the Chief Executive Officer and President of International Technidyne Corporation, a developer of point-of-care cardiovascular diagnostic testing solutions. Mr. Sperzel received his Bachelor of Science degree in Business Administration/Management from Plymouth State College. - John Sperzel自2020年1月起担任我们的总裁兼首席执行官兼董事会成员。2014年3月至2020年1月，Sperzel先生担任ChembioDiagnostics，Inc.的首席执行官、总裁兼董事会成员，该公司是一家专注于传染病的定点诊断公司。从2011年9月到2013年12月，Sperzel先生担任International Technidyne Corporation的首席执行官兼总裁，这是一家护理点心血管诊断测试解决方案的开发商。Sperzel先生在普利茅斯州立学院（Plymouth State College）获得工商管理/管理理学学士学位。
- John Sperzel,has served as T2 Biosystems, Inc. President and Chief Executive Officer and a member of T2 Biosystems, Inc. Board of Directors since January 2020 and has served as Chairman of T2 Biosystems, Inc. Board of Directors since July 2021. From March 2014 to January 2020, Mr. Sperzel was the Chief Executive Officer, President and a member of the Board of Directors of Chembio Diagnostics, Inc., a point-of-care diagnostics company focused on infectious diseases. From September 2011 to December 2013, Mr. Sperzel was the Chief Executive Officer and President of International Technidyne Corporation, a developer of point-of-care cardiovascular diagnostic testing solutions. Mr. Sperzel received his Bachelor of Science degree in Business Administration/Management from Plymouth State College.
- Ninfa Saunders
-
Ninfa Saunders自2020年6月起担任我们的董事会成员。Saunders女士自2012年10月以来一直受雇于Navicent Health，该公司是格鲁吉亚第二大医院，她目前是该公司的总裁兼首席执行官。在加入Navicent Health之前，桑德斯女士于2003年至2012年担任Virtua Health的总裁兼首席运营官，Virtua Health是新泽西州南部最大的卫生系统。桑德斯博士拥有南卡罗来纳医科大学梦百合管理博士学位、埃默里大学工商管理硕士学位、罗格斯大学护理理学硕士学位和康科迪亚学院护理理学学士学位。
Ninfa Saunders,has served as a member of T2 Biosystems, Inc. Board of Directors since June 2020. Ms. Saunders served as President and Chief Executive Officer of Navicent Health, the second largest hospital in Georgia from October 2012 to October 2020. Prior to joining Navicent Health, Ms. Saunders served as President and COO of Virtua Health, the largest health system in southern New Jersey, from 2003 to 2012. Dr. Saunders has a Doctorate in Healthcare Administration from the Medical University of South Carolina, a Master's of Business Administration from Emory University, a Master of Science in Nursing from Rutgers University and a Bachelor of Science in Nursing from Concordia College. - Ninfa Saunders自2020年6月起担任我们的董事会成员。Saunders女士自2012年10月以来一直受雇于Navicent Health，该公司是格鲁吉亚第二大医院，她目前是该公司的总裁兼首席执行官。在加入Navicent Health之前，桑德斯女士于2003年至2012年担任Virtua Health的总裁兼首席运营官，Virtua Health是新泽西州南部最大的卫生系统。桑德斯博士拥有南卡罗来纳医科大学梦百合管理博士学位、埃默里大学工商管理硕士学位、罗格斯大学护理理学硕士学位和康科迪亚学院护理理学学士学位。
- Ninfa Saunders,has served as a member of T2 Biosystems, Inc. Board of Directors since June 2020. Ms. Saunders served as President and Chief Executive Officer of Navicent Health, the second largest hospital in Georgia from October 2012 to October 2020. Prior to joining Navicent Health, Ms. Saunders served as President and COO of Virtua Health, the largest health system in southern New Jersey, from 2003 to 2012. Dr. Saunders has a Doctorate in Healthcare Administration from the Medical University of South Carolina, a Master's of Business Administration from Emory University, a Master of Science in Nursing from Rutgers University and a Bachelor of Science in Nursing from Concordia College.
- Robin Toft
-
Robin Toft自2020年6月起担任我们的董事会成员。Toft女士自2010年7月以来一直受雇于Toft Group Executive Search，该公司是一家高管猎头公司，专注于生物技术，制药，诊断，医疗设备，生命科学工具和梦百合高科技公司，目前担任总裁。在Toft Group高管猎头之前，Toft女士从2006年到2010年受雇于Sanford Rose Associates-Toft Group。在此之前，Toft女士于2003年1月至2005年11月受雇于罗氏诊断公司（Roche Diagnostics），该公司是一家诊断公司，生产用于研究和医疗诊断应用的设备和试剂，担任商业运营的高级副总裁。Toft女士拥有密歇根州立大学（Michigan State University）医学技术临床实验室科学的B.S.。
Robin Toft,has served as a member of T2 Biosystems, Inc. Board of Directors since June 2020. Ms. Toft has been employed by ZRG Partners (formerly Toft Group), an executive search firm that focuses on biotechnology, pharmaceutical, diagnostics, medical device, life science tools and healthcare high tech companies since July 2010 and currently serves as Advisor Global Life Sciences & Board Diversity. Prior to the ZRG Partners, Ms. Toft was employed by Sanford Rose Associates – Toft Group from 2006 to 2010. Prior to that, Ms. Toft was employed by Roche Diagnostics, a diagnostics company that manufactures equipment and reagents for research and medical diagnostic applications from January 2003 to November 2005, as Senior Vice President of Commercial Operations. Ms. Toft holds a B.S. in Medical Technology (Clinical Laboratory Science) from Michigan State University. - Robin Toft自2020年6月起担任我们的董事会成员。Toft女士自2010年7月以来一直受雇于Toft Group Executive Search，该公司是一家高管猎头公司，专注于生物技术，制药，诊断，医疗设备，生命科学工具和梦百合高科技公司，目前担任总裁。在Toft Group高管猎头之前，Toft女士从2006年到2010年受雇于Sanford Rose Associates-Toft Group。在此之前，Toft女士于2003年1月至2005年11月受雇于罗氏诊断公司（Roche Diagnostics），该公司是一家诊断公司，生产用于研究和医疗诊断应用的设备和试剂，担任商业运营的高级副总裁。Toft女士拥有密歇根州立大学（Michigan State University）医学技术临床实验室科学的B.S.。
- Robin Toft,has served as a member of T2 Biosystems, Inc. Board of Directors since June 2020. Ms. Toft has been employed by ZRG Partners (formerly Toft Group), an executive search firm that focuses on biotechnology, pharmaceutical, diagnostics, medical device, life science tools and healthcare high tech companies since July 2010 and currently serves as Advisor Global Life Sciences & Board Diversity. Prior to the ZRG Partners, Ms. Toft was employed by Sanford Rose Associates – Toft Group from 2006 to 2010. Prior to that, Ms. Toft was employed by Roche Diagnostics, a diagnostics company that manufactures equipment and reagents for research and medical diagnostic applications from January 2003 to November 2005, as Senior Vice President of Commercial Operations. Ms. Toft holds a B.S. in Medical Technology (Clinical Laboratory Science) from Michigan State University.
- Laura Adams
-
Laura Adams，自2021年10月起担任T2 Biosystems, Inc.董事会成员。自1998年以来，亚当斯女士一直担任劳拉·亚当斯咨询公司的负责人，这是一家服务于医疗保健行业的战略咨询公司。自2019年11月以来，亚当斯女士一直担任国家医学科学院特别顾问，该机构是一个非政府组织，就数字健康、医学、健康政策和生物医学相关问题提供国家和国际咨询。从2019年4月到2021年4月，她担任X4 Health的Catalyst，该公司与卫生系统合作，与患者和家属合作设计新的护理方案。从2001年到2019年，她是罗德岛质量研究所的创始人和首席执行官，这是一个促进健康和护理信息的合作创新中心。亚当斯女士获得了北科罗拉多大学的理学学士学位和北科罗拉多大学健康中心的理学硕士学位。
Laura Adams,has served as a member of T2 Biosystems, Inc. Board of Directors since October 2021. Since 1998, Ms. Adams has been Principal at Laura Adams Consulting, a strategic advisory firm serving the healthcare industry. Ms. Adams has served as Special Adviser to the National Academy of Medicine, a non-governmental organization that provides national and international advice on issues relating to digital health, medicine, health policy, and biomedical science, since November 2019. From April 2019 to April 2021 she served as a Catalyst for X4 Health, a company working with health systems to partner with patients and families in new designs of care. From 2001 to 2019 she was the Founder and Chief Executive Officer of The Rhode Island Quality Institute, a center for collaborative innovation that advances health and care information. Ms. Adams received a Bachelor of Science from the University of Northern Colorado and a Masters of Science from the University of Northern Colorado Health Center. - Laura Adams，自2021年10月起担任T2 Biosystems, Inc.董事会成员。自1998年以来，亚当斯女士一直担任劳拉·亚当斯咨询公司的负责人，这是一家服务于医疗保健行业的战略咨询公司。自2019年11月以来，亚当斯女士一直担任国家医学科学院特别顾问，该机构是一个非政府组织，就数字健康、医学、健康政策和生物医学相关问题提供国家和国际咨询。从2019年4月到2021年4月，她担任X4 Health的Catalyst，该公司与卫生系统合作，与患者和家属合作设计新的护理方案。从2001年到2019年，她是罗德岛质量研究所的创始人和首席执行官，这是一个促进健康和护理信息的合作创新中心。亚当斯女士获得了北科罗拉多大学的理学学士学位和北科罗拉多大学健康中心的理学硕士学位。
- Laura Adams,has served as a member of T2 Biosystems, Inc. Board of Directors since October 2021. Since 1998, Ms. Adams has been Principal at Laura Adams Consulting, a strategic advisory firm serving the healthcare industry. Ms. Adams has served as Special Adviser to the National Academy of Medicine, a non-governmental organization that provides national and international advice on issues relating to digital health, medicine, health policy, and biomedical science, since November 2019. From April 2019 to April 2021 she served as a Catalyst for X4 Health, a company working with health systems to partner with patients and families in new designs of care. From 2001 to 2019 she was the Founder and Chief Executive Officer of The Rhode Island Quality Institute, a center for collaborative innovation that advances health and care information. Ms. Adams received a Bachelor of Science from the University of Northern Colorado and a Masters of Science from the University of Northern Colorado Health Center.
- Jack Cumming
-
Jack Cumming，自2014年7月起担任T2 Biosystems, Inc.董事会成员，自2020年6月起担任首席独立董事。他还担任TransMed7，LLC董事会成员。Cumming先生目前担任Cumming & Associates LLC的首席执行官和董事总经理，Cumming & Associates LLC是一家服务于医疗保健行业的战略咨询公司。从2000年8月至2013年12月，卡明先生在诊断公司Hologic Inc.担任多个领导职务，包括2001年至2009年担任首席执行官，2013年7月至2013年12月再次担任首席执行官，2001年至2003年担任总裁，2002年至2007年担任董事会主席，2008年至2011年再次担任董事会主席，2011年至2013年7月担任全球战略顾问。卡明先生就读于南卡罗来纳大学。
Jack Cumming,has served as a member of T2 Biosystems, Inc. Board of Directors since July 2014 and Lead Independent Director since June 2020. He also serves as a member of the Board of Directors of TransMed7, LLC. Mr. Cumming currently serves as Chief Executive Officer and Managing Director of Cumming & Associates LLC, a strategic advisory firm serving the healthcare industry. From August 2000 until December 2013, Mr. Cumming served in a number of leadership roles at Hologic Inc., a diagnostics company, including as Chief Executive Officer from 2001 through 2009 and again from July 2013 through December 2013, as President from 2001 until 2003, as Chairman of the Board from 2002 until 2007 and again from 2008 through 2011, and as Global Strategic Advisor from 2011 through July 2013. Mr. Cumming attended the University of South Carolina. - Jack Cumming，自2014年7月起担任T2 Biosystems, Inc.董事会成员，自2020年6月起担任首席独立董事。他还担任TransMed7，LLC董事会成员。Cumming先生目前担任Cumming & Associates LLC的首席执行官和董事总经理，Cumming & Associates LLC是一家服务于医疗保健行业的战略咨询公司。从2000年8月至2013年12月，卡明先生在诊断公司Hologic Inc.担任多个领导职务，包括2001年至2009年担任首席执行官，2013年7月至2013年12月再次担任首席执行官，2001年至2003年担任总裁，2002年至2007年担任董事会主席，2008年至2011年再次担任董事会主席，2011年至2013年7月担任全球战略顾问。卡明先生就读于南卡罗来纳大学。
- Jack Cumming,has served as a member of T2 Biosystems, Inc. Board of Directors since July 2014 and Lead Independent Director since June 2020. He also serves as a member of the Board of Directors of TransMed7, LLC. Mr. Cumming currently serves as Chief Executive Officer and Managing Director of Cumming & Associates LLC, a strategic advisory firm serving the healthcare industry. From August 2000 until December 2013, Mr. Cumming served in a number of leadership roles at Hologic Inc., a diagnostics company, including as Chief Executive Officer from 2001 through 2009 and again from July 2013 through December 2013, as President from 2001 until 2003, as Chairman of the Board from 2002 until 2007 and again from 2008 through 2011, and as Global Strategic Advisor from 2011 through July 2013. Mr. Cumming attended the University of South Carolina.
- David B. Elsbree
-
David B. Elsbree，他曾担任T2 Biosystems, Inc.的成员。自2014年7月起担任董事会成员。从1970年到2004年，他受雇于德勤（Deloitte & Touche），最近担任高级合伙人。他曾担任公司高科技业务的多个领导职务，包括负责新英格兰高科技业务的合伙人。2004年6月至2011年1月，他担任Art Technology Group, Inc.的董事会成员；2006年11月至2013年3月，他担任Acme Packet, Inc.的董事会成员。他获得Northeastern University学士学位。
David B. Elsbree,has served as a member of T2 Biosystems, Inc. Board of Directors since July 2014. From 1970 until 2004, Mr. Elsbree was employed by Deloitte & Touche, most recently as a senior partner. Mr. Elsbree served in a number of leadership roles in the firm's high technology practice, including partner-in-charge of the New England High Technology Practice. Mr. Elsbree served on the Board of Directors of Art Technology Group, Inc. from June 2004 until January 2011 and on the board of directors of Acme Packet, Inc. from November 2006 until March 2013. Mr. Elsbree received his B.A. from Northeastern University. - David B. Elsbree，他曾担任T2 Biosystems, Inc.的成员。自2014年7月起担任董事会成员。从1970年到2004年，他受雇于德勤（Deloitte & Touche），最近担任高级合伙人。他曾担任公司高科技业务的多个领导职务，包括负责新英格兰高科技业务的合伙人。2004年6月至2011年1月，他担任Art Technology Group, Inc.的董事会成员；2006年11月至2013年3月，他担任Acme Packet, Inc.的董事会成员。他获得Northeastern University学士学位。
- David B. Elsbree,has served as a member of T2 Biosystems, Inc. Board of Directors since July 2014. From 1970 until 2004, Mr. Elsbree was employed by Deloitte & Touche, most recently as a senior partner. Mr. Elsbree served in a number of leadership roles in the firm's high technology practice, including partner-in-charge of the New England High Technology Practice. Mr. Elsbree served on the Board of Directors of Art Technology Group, Inc. from June 2004 until January 2011 and on the board of directors of Acme Packet, Inc. from November 2006 until March 2013. Mr. Elsbree received his B.A. from Northeastern University.
高管简历
中英对照 | 中文 | 英文- Michael Gibbs
Michael Gibbs，曾担任T2 Biosystems, Inc.高级副总裁兼总法律顾问（2016年1月以来）。Gibbs先生于2014年12月加入T2 Biosystems, Inc.担任高级企业法律顾问。从2011年到加入T2 Biosystems, Inc.公司，Gibbs先生担任Keystone Dental, Inc.（一家专注于牙科植入物和生物材料的医疗设备公司）的总法律顾问。从2003年到2011年，Gibbs先生是律师事务所Bingham McCutchen LLP（现为Morgan Lewis & Bockius）的公司律师。在加入Bingham McCutchen LLP之前，他是美国海军陆战队的一名军官，以少校的军衔离开。Gibbs先生获得了Boston College Law School的法学博士学位和Syracuse University的政治学学士学位。
Michael Gibbs,has served as T2 Biosystems, Inc. Senior Vice President and General Counsel since January 2016. Mr. Gibbs joined T2 Biosystems, Inc. in December 2014 as Senior Corporate Counsel. From 2011 until he joined T2 Biosystems, Inc. company, Mr. Gibbs was General Counsel for Keystone Dental, Inc., a medical device company focused on dental implants and biomaterials. From 2003 to 2011, Mr. Gibbs was a corporate attorney with the law firm Bingham McCutchen LLP (now Morgan Lewis & Bockius). Prior to joining Bingham McCutchen LLP, he was an officer in the United States Marine Corps, departing with the rank of Major. Mr. Gibbs received his J.D. from Boston College Law School and his B.S. in Political Science from Syracuse University.- Michael Gibbs，曾担任T2 Biosystems, Inc.高级副总裁兼总法律顾问（2016年1月以来）。Gibbs先生于2014年12月加入T2 Biosystems, Inc.担任高级企业法律顾问。从2011年到加入T2 Biosystems, Inc.公司，Gibbs先生担任Keystone Dental, Inc.（一家专注于牙科植入物和生物材料的医疗设备公司）的总法律顾问。从2003年到2011年，Gibbs先生是律师事务所Bingham McCutchen LLP（现为Morgan Lewis & Bockius）的公司律师。在加入Bingham McCutchen LLP之前，他是美国海军陆战队的一名军官，以少校的军衔离开。Gibbs先生获得了Boston College Law School的法学博士学位和Syracuse University的政治学学士学位。
- Michael Gibbs,has served as T2 Biosystems, Inc. Senior Vice President and General Counsel since January 2016. Mr. Gibbs joined T2 Biosystems, Inc. in December 2014 as Senior Corporate Counsel. From 2011 until he joined T2 Biosystems, Inc. company, Mr. Gibbs was General Counsel for Keystone Dental, Inc., a medical device company focused on dental implants and biomaterials. From 2003 to 2011, Mr. Gibbs was a corporate attorney with the law firm Bingham McCutchen LLP (now Morgan Lewis & Bockius). Prior to joining Bingham McCutchen LLP, he was an officer in the United States Marine Corps, departing with the rank of Major. Mr. Gibbs received his J.D. from Boston College Law School and his B.S. in Political Science from Syracuse University.
- John Sprague
John Sprague自2018年1月起担任我们的首席财务官。在加入我们公司之前，斯普拉格先生是Caliber Imaging&Diagnostics，Inc.的首席财务官，该公司是一家医疗技术设计公司，从2017年2月至2018年1月，开发和销售创新的数字成像解决方案，该解决方案使用专为病理和生命科学成像皮肤和其他组织而设计的体内共焦显微镜在细胞水平上显示组织。从2011年到2017年，斯普拉格先生在通用电气梦百合担任过多个职位，最后一项任务是担任通用电气北美核心影像业务的财务经理。Sprague先生是一名注册会计师，在波士顿学院（Boston College）获得会计学学士学位。
John Sprague,has served as T2 Biosystems, Inc. Chief Financial Officer since January 2018. Prior to joining T2 Biosystems, Inc. company, Mr. Sprague was Chief Financial Officer at Caliber Imaging & Diagnostics, Inc., a medical technologies company that designs, develops and markets innovative digital imaging solutions that show tissue at the cellular level T2 Biosystems, Inc. ing in-vivo confocal microscopes designed specifically for imaging skin and other tissues for pathology and life sciences, from February 2017 to January 2018. From 2011 to 2017, Mr. Sprague held various positions at GE Healthcare, with his last assignment serving as Finance Manager of GE's North American Core Imaging business. Mr. Sprague is a certified public accountant and received his B.S. in accounting from Boston College.- John Sprague自2018年1月起担任我们的首席财务官。在加入我们公司之前，斯普拉格先生是Caliber Imaging&Diagnostics，Inc.的首席财务官，该公司是一家医疗技术设计公司，从2017年2月至2018年1月，开发和销售创新的数字成像解决方案，该解决方案使用专为病理和生命科学成像皮肤和其他组织而设计的体内共焦显微镜在细胞水平上显示组织。从2011年到2017年，斯普拉格先生在通用电气梦百合担任过多个职位，最后一项任务是担任通用电气北美核心影像业务的财务经理。Sprague先生是一名注册会计师，在波士顿学院（Boston College）获得会计学学士学位。
- John Sprague,has served as T2 Biosystems, Inc. Chief Financial Officer since January 2018. Prior to joining T2 Biosystems, Inc. company, Mr. Sprague was Chief Financial Officer at Caliber Imaging & Diagnostics, Inc., a medical technologies company that designs, develops and markets innovative digital imaging solutions that show tissue at the cellular level T2 Biosystems, Inc. ing in-vivo confocal microscopes designed specifically for imaging skin and other tissues for pathology and life sciences, from February 2017 to January 2018. From 2011 to 2017, Mr. Sprague held various positions at GE Healthcare, with his last assignment serving as Finance Manager of GE's North American Core Imaging business. Mr. Sprague is a certified public accountant and received his B.S. in accounting from Boston College.
- John Sperzel
John Sperzel自2020年1月起担任我们的总裁兼首席执行官兼董事会成员。2014年3月至2020年1月，Sperzel先生担任ChembioDiagnostics，Inc.的首席执行官、总裁兼董事会成员，该公司是一家专注于传染病的定点诊断公司。从2011年9月到2013年12月，Sperzel先生担任International Technidyne Corporation的首席执行官兼总裁，这是一家护理点心血管诊断测试解决方案的开发商。Sperzel先生在普利茅斯州立学院（Plymouth State College）获得工商管理/管理理学学士学位。
John Sperzel,has served as T2 Biosystems, Inc. President and Chief Executive Officer and a member of T2 Biosystems, Inc. Board of Directors since January 2020 and has served as Chairman of T2 Biosystems, Inc. Board of Directors since July 2021. From March 2014 to January 2020, Mr. Sperzel was the Chief Executive Officer, President and a member of the Board of Directors of Chembio Diagnostics, Inc., a point-of-care diagnostics company focused on infectious diseases. From September 2011 to December 2013, Mr. Sperzel was the Chief Executive Officer and President of International Technidyne Corporation, a developer of point-of-care cardiovascular diagnostic testing solutions. Mr. Sperzel received his Bachelor of Science degree in Business Administration/Management from Plymouth State College.- John Sperzel自2020年1月起担任我们的总裁兼首席执行官兼董事会成员。2014年3月至2020年1月，Sperzel先生担任ChembioDiagnostics，Inc.的首席执行官、总裁兼董事会成员，该公司是一家专注于传染病的定点诊断公司。从2011年9月到2013年12月，Sperzel先生担任International Technidyne Corporation的首席执行官兼总裁，这是一家护理点心血管诊断测试解决方案的开发商。Sperzel先生在普利茅斯州立学院（Plymouth State College）获得工商管理/管理理学学士学位。
- John Sperzel,has served as T2 Biosystems, Inc. President and Chief Executive Officer and a member of T2 Biosystems, Inc. Board of Directors since January 2020 and has served as Chairman of T2 Biosystems, Inc. Board of Directors since July 2021. From March 2014 to January 2020, Mr. Sperzel was the Chief Executive Officer, President and a member of the Board of Directors of Chembio Diagnostics, Inc., a point-of-care diagnostics company focused on infectious diseases. From September 2011 to December 2013, Mr. Sperzel was the Chief Executive Officer and President of International Technidyne Corporation, a developer of point-of-care cardiovascular diagnostic testing solutions. Mr. Sperzel received his Bachelor of Science degree in Business Administration/Management from Plymouth State College.
- Roger Smith
Roger Smith，自2022年3月起担任科学研究与发展高级副总裁。史密斯先生于2014年1月加入T2 Biosystems公司，担任化验开发高级经理。从2011年到2014年加入T2 Biosystems公司，他是Semprus Biosciences的微生物学主管，该公司专注于开发用于医疗设备的新型耐微生物表面。从2007年到2012年，他在博德研究所担任微生物遗传学负责人，专注于生产微生物文库，即T2 Biosystems公司为新药发现而设计的文库。史密斯博士在罗切斯特大学获得微生物学博士学位，并在哈佛医学院完成博士后研究。他在微生物学和医疗器械领域撰写了许多科学出版物，并拥有多项专利。
Roger Smith,has served as the Senior Vice President of Science Research and Development since March 2022. Mr. Smith joined T2 Biosystems, Inc. in January 2014 as Senior Manager of Assay Development. From 2011 until joining T2 Biosystems, Inc. in 2014 he was Head of Microbiology at Semprus Biosciences, a company focused on the development of novel microbial resistant surfaces for medical devices. From 2007 to 2012 he was Head of Microbial Genetics at the Broad Institute focused on the production of microbial libraries that were T2 Biosystems, Inc. ed for novel drug discovery. Dr. Smith received his Ph.D. in microbiology from the University of Rochester and completed post-doctoral studies at Harvard Medical School. He has authored numerous scientific publications in the fields of microbiology and medical devices and holds several patents.- Roger Smith，自2022年3月起担任科学研究与发展高级副总裁。史密斯先生于2014年1月加入T2 Biosystems公司，担任化验开发高级经理。从2011年到2014年加入T2 Biosystems公司，他是Semprus Biosciences的微生物学主管，该公司专注于开发用于医疗设备的新型耐微生物表面。从2007年到2012年，他在博德研究所担任微生物遗传学负责人，专注于生产微生物文库，即T2 Biosystems公司为新药发现而设计的文库。史密斯博士在罗切斯特大学获得微生物学博士学位，并在哈佛医学院完成博士后研究。他在微生物学和医疗器械领域撰写了许多科学出版物，并拥有多项专利。
- Roger Smith,has served as the Senior Vice President of Science Research and Development since March 2022. Mr. Smith joined T2 Biosystems, Inc. in January 2014 as Senior Manager of Assay Development. From 2011 until joining T2 Biosystems, Inc. in 2014 he was Head of Microbiology at Semprus Biosciences, a company focused on the development of novel microbial resistant surfaces for medical devices. From 2007 to 2012 he was Head of Microbial Genetics at the Broad Institute focused on the production of microbial libraries that were T2 Biosystems, Inc. ed for novel drug discovery. Dr. Smith received his Ph.D. in microbiology from the University of Rochester and completed post-doctoral studies at Harvard Medical School. He has authored numerous scientific publications in the fields of microbiology and medical devices and holds several patents.
- Brett Giffin
Brett Giffin，自2021年11月起担任T2 Biosystems, Inc.首席商务官。在加入公司之前，吉芬曾担任Mancini Burfield Edgerton的董事总经理，该公司是一家保留下来的猎头和管理咨询公司，从2019年4月至2021年11月专注于生命科学。2017年9月至2019年4月，吉芬先生担任Fibronostics的首席执行官，这是一家医疗保健技术公司，开发基于算法的诊断测试并将其商业化。2015年6月至2017年9月，吉芬先生担任3SI Systems，LLC的首席执行官兼总裁，该公司是一家医疗保健技术公司，提供一种基于IT的新颖的软件和硬件语音识别工作流程系统。吉芬先生在克里斯托弗纽波特大学获得政治学学士学位，在菲尼克斯大学获得工商管理硕士学位。
Brett Giffin,has served as T2 Biosystems, Inc. Chief Commercial Officer since November 2021. Prior to joining the company, Mr. Giffin served as a Managing Director for Mancini Burfield Edgerton, a retained executive search and management consulting firm focused on life sciences from April 2019 until November 2021. From September 2017 to April 2019, Mr. Giffin was the Chief Executive Officer of Fibronostics, a healthcare technology company developing and commercializing algorithm-based diagnostic tests. From June 2015 to September 2017, Mr. Giffin was the Chief Executive Officer and President of 3SI Systems, LLC, a healthcare technology company offering a novel software and hardware IT based speech recognition workflow system. Mr. Giffin received a Bachelor of Arts degree in Political Science from Christopher Newport University and a Masters degree in Business Administration from the University of Phoenix.- Brett Giffin，自2021年11月起担任T2 Biosystems, Inc.首席商务官。在加入公司之前，吉芬曾担任Mancini Burfield Edgerton的董事总经理，该公司是一家保留下来的猎头和管理咨询公司，从2019年4月至2021年11月专注于生命科学。2017年9月至2019年4月，吉芬先生担任Fibronostics的首席执行官，这是一家医疗保健技术公司，开发基于算法的诊断测试并将其商业化。2015年6月至2017年9月，吉芬先生担任3SI Systems，LLC的首席执行官兼总裁，该公司是一家医疗保健技术公司，提供一种基于IT的新颖的软件和硬件语音识别工作流程系统。吉芬先生在克里斯托弗纽波特大学获得政治学学士学位，在菲尼克斯大学获得工商管理硕士学位。
- Brett Giffin,has served as T2 Biosystems, Inc. Chief Commercial Officer since November 2021. Prior to joining the company, Mr. Giffin served as a Managing Director for Mancini Burfield Edgerton, a retained executive search and management consulting firm focused on life sciences from April 2019 until November 2021. From September 2017 to April 2019, Mr. Giffin was the Chief Executive Officer of Fibronostics, a healthcare technology company developing and commercializing algorithm-based diagnostic tests. From June 2015 to September 2017, Mr. Giffin was the Chief Executive Officer and President of 3SI Systems, LLC, a healthcare technology company offering a novel software and hardware IT based speech recognition workflow system. Mr. Giffin received a Bachelor of Arts degree in Political Science from Christopher Newport University and a Masters degree in Business Administration from the University of Phoenix.